Large state-wide variation (8.6-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2018 ^a indicates ≥1.50 SD (17.9) from the mean (32.9... by Luke R. Cavanah (19022435)

Large state-wide variation (11.1-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2015 ^a indicates ≥1.50 SD (20.2) from the mean (36.... by Luke R. Cavanah (19022435)

Large state-wide variation (8.6-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2017 ^a indicates ≥1.50 SD (18.0) from the mean (33.1... by Luke R. Cavanah (19022435)

Large state-wide variation (8.5-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2019 ^a indicates ≥1.50 SD (16.8) from the mean (31.0... by Luke R. Cavanah (19022435)

Large state-wide variation (8.6-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2020 ^a indicates ≥1.50 SD (16.0) from the mean (29.9... by Luke R. Cavanah (19022435)

Protective effects of DEX on TNF-α-induced cochlear hair cells loss in cochlear explants. by Byung Chul Kang (1905025)

Subjects:

Effects of TNF-α on the cochlear hair cells in middle-turn cochlear explants. by Byung Chul Kang (1905025)

Subjects:

Attenuation of TNF-α-induced apoptosis through pretreatment of DEX in cochlear explants. by Byung Chul Kang (1905025)

Subjects:

Detection of the Challenging mutations at 1% VAF and 50 ng DNA input. by Lizhi Yu (12476136)

Subjects:

Effects of DEX and TNF-α on intracellular ROS accumulation and expression of apoptosis-related proteins. by Byung Chul Kang (1905025)

Subjects:

Protective effect of DEX on cell viability, ROS generation, and expression of apoptosis-related proteins in TNF-α-treated cells. by Byung Chul Kang (1905025)

Subjects:

Attenuation of TNF-α-induced apoptosis by DEX pretreatment. by Byung Chul Kang (1905025)

Subjects:

Fig 1 - by Byung Chul Kang (1905025)

Subjects:

Cytotoxicity (as of %Control) IC₅₀ value (mean ±SD in µM) of the tested compounds vs. positive controls Cisplatin and doxorubicin against other malignancy’ cell lines ad... by MohammedBashar Al-Qazzan (22439236)

Measurement of ATP production in HL-1 cells exposed for 12 or 72h to LG, NG, HG or IHG. by Patrick Mordel (17020879)

<i>Aspergillus flavus</i> mRNA expression (a) <i>aflD</i> and (c) <i>aflR</i> and phylogenetic analysis of (b) <i>aflD</i> and (d) <i>aflR</i> after exposure to 50 mg/mL of <i>U. e... by Martha Cebile Jobe (21175426)

Baseline clinical profile of hospitalized COVID-19 patients with low and high renalase. by Basmah Safdar (12213257)

Cox hazard regression model of renalase and primary composite outcome. by Basmah Safdar (12213257)

Flow chart of study patients from all COVID-19 admissions to the institution from March to July 2020. by Basmah Safdar (12213257)

Time adjusted survival curves for high vs. low renalase among patients with COVID-19 disease (using first quartile as cutoff). by Basmah Safdar (12213257)